Gary Nachman
Stock Analyst at Raymond James
(3.76)
# 728
Out of 4,974 analysts
95
Total ratings
60.56%
Success rate
5.63%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Assumes: Market Perform | n/a | $283.64 | - | 2 | Sep 3, 2025 | |
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $3.37 | +493.47% | 2 | Aug 13, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $227 → $236 | $212.56 | +11.03% | 16 | Aug 1, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Outperform | $39 → $40 | $41.98 | -4.72% | 2 | Jul 31, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Strong Buy | $60 → $64 | $61.23 | +4.52% | 3 | Jul 31, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $19.13 | +46.37% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $452.00 | -34.07% | 7 | Nov 1, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $2.83 | +606.71% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $26.45 | +39.89% | 13 | Jul 31, 2024 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $19 | $15.01 | +26.58% | 1 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $30 | $31.41 | -4.49% | 5 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $5.42 | +29.15% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $129.50 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $9.62 | -58.42% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $12.34 | +143.11% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $4.22 | +658.29% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $10.50 | +33.33% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $18.95 | -47.23% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $41.34 | -27.43% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $3.45 | +21,639.13% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $7.35 | +8.84% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $29.43 | -28.64% | 5 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $14 | $5.57 | +151.35% | 2 | Jun 14, 2018 |
Amgen
Sep 3, 2025
Assumes: Market Perform
Price Target: n/a
Current: $283.64
Upside: -
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $3.37
Upside: +493.47%
AbbVie
Aug 1, 2025
Maintains: Outperform
Price Target: $227 → $236
Current: $212.56
Upside: +11.03%
LENZ Therapeutics
Jul 31, 2025
Maintains: Outperform
Price Target: $39 → $40
Current: $41.98
Upside: -4.72%
Ionis Pharmaceuticals
Jul 31, 2025
Maintains: Strong Buy
Price Target: $60 → $64
Current: $61.23
Upside: +4.52%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $19.13
Upside: +46.37%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $452.00
Upside: -34.07%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $2.83
Upside: +606.71%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $26.45
Upside: +39.89%
Bausch + Lomb
Jul 10, 2024
Initiates: Outperform
Price Target: $19
Current: $15.01
Upside: +26.58%
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $31.41
Upside: -4.49%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $5.42
Upside: +29.15%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $129.50
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $9.62
Upside: -58.42%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $12.34
Upside: +143.11%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $4.22
Upside: +658.29%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $10.50
Upside: +33.33%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $18.95
Upside: -47.23%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $41.34
Upside: -27.43%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $3.45
Upside: +21,639.13%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $7.35
Upside: +8.84%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $29.43
Upside: -28.64%
Jun 14, 2018
Maintains: Outperform
Price Target: $24 → $14
Current: $5.57
Upside: +151.35%